# Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

> **NCT07146022** · PHASE3 · RECRUITING · sponsor: **Veradermics, Inc.** · enrollment: 552 (estimated)

## Conditions studied

- Androgenetic Alopecia (AGA)
- Androgenetic Alopecia
- AGA
- Female Androgenetic Alopecia
- Hair Loss

## Interventions

- **DRUG:** VDPHL01 QD
- **DRUG:** Placebo
- **DRUG:** VDPHL01 BID
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07146022
- **Lead sponsor:** Veradermics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-25
- **Primary completion:** 2027-06
- **Final completion:** 2028-01
- **Target enrollment:** 552 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07146022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07146022, "Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT07146022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*